Quantcast

Latest Rosuvastatin Stories

2010-03-02 07:30:00

OSAKA, Japan, ATLANTA and ANN ARBOR, Mich., March 2 /PRNewswire/ -- Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company, a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator ("SERM"). Under the terms of this agreement, Shionogi will have worldwide marketing rights to ospemifene. QuatRx will receive an up-front payment of $25 million and is eligible...

2010-02-08 18:09:00

WILMINGTON, Del., Feb. 8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved CRESTOR® (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men greater than or equal to 50 and women...

2009-12-15 16:58:00

WILMINGTON, Del., Dec. 15 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR® (rosuvastatin calcium) in individuals meeting the following criteria: Men greater than or equal to 50 years, women greater than or equal to 60 years; Fasting LDL...

2009-12-11 10:32:00

WILMINGTON, Del., Dec. 11 /PRNewswire-FirstCall/ -- Today, the U.S. Food and Drug Administration (FDA) posted briefing materials in advance of the December 15(th) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) to discuss the supplemental New Drug Application (sNDA) filed by AstraZeneca (NYSE: AZN). The briefing materials can be found on the FDA web site. (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) In July, AstraZeneca announced that it had filed an...

2009-11-17 15:00:00

ORLANDO, Fla., Nov. 17 /PRNewswire/ -- A new analysis of 6,801 women in the JUPITER study showed CRESTOR® (rosuvastatin calcium) 20 mg significantly reduced cardiovascular (CV) events (defined as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by nearly half (46 percent; p=0.002 vs. placebo) in women without cardiovascular disease (CVD), but at increased risk of a cardiovascular...

2009-11-09 05:28:00

NANJING, China, Nov. 9 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd. ("Tianda"). The acquisition of the manufacturing license will be effected through the...

2009-10-16 07:00:00

WILMINGTON, Del., Oct. 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the U.S. Food and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease....

2009-09-01 07:00:00

WILMINGTON, Del., Sept. 1 /PRNewswire-FirstCall/ -- Recognizing that September is National Cholesterol Education Month (NCEM), AstraZeneca (NYSE: AZN) is urging all adults, especially the 98.6 million Americans over the age of 20 years old with high cholesterol (1), to talk to their doctors about elevated cholesterol and get their cholesterol levels checked. Elevated cholesterol can contribute to the buildup of plaque in the arteries, also known as atherosclerosis, which can begin in early...

2009-08-31 07:00:00

BARCELONA, Spain, Aug. 31 /PRNewswire/ -- A new analysis from the JUPITER study showed that CRESTOR((R)) (rosuvastatin calcium) 20mg reduced the composite primary end point of major cardiovascular (CV) events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39% (p<0.001), compared to placebo, in elderly patients with LDL-C less than 130 mg/dL and elevated high-sensitivity C-reactive protein (hsCRP). This analysis...

2009-08-12 08:39:00

WALTHAM, Mass., Aug. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Merck/Schering-Plough's Zetia and Vytorin have lost substantial patient share in second- and third-line therapy since last year's analysis of the dyslipidemia drug market. This decline is most likely attributed to the publication of the ENHANCE trial which called into question the ability of these agents to improve...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related